Cybin Inc (CYBN) Stock Price, Quote & News

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology

Sector: Healthcare

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

LiquidThetaLEAPS Oct. 7 at 9:12 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CYBN Current Share Price: $6.34 Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.50- $1.83 Scale out: $2.33-$2.99 Can Easily Capture: 60% ROI Blended DTE: 221 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

BobJohnBuoy666 Oct. 6 at 9:14 PM

$CYBN nice Adam / Eve double bottom. Daddy wants to get paid!

0 · Reply

PsychedStocks Oct. 6 at 6:43 PM

$CYBN $CYBHF $BBAI

0 · Reply

finck Oct. 6 at 6:34 PM

$CYBN lets get to $28 per share first and then we can start to get excited

0 · Reply

Rico_Again_Jorge Oct. 6 at 5:04 PM

$CYBN Wow. Another good time to short

0 · Reply

HughJasol Oct. 6 at 3:48 PM

$CYBN this will be back at 5 before it hits 8, let alone you pumper trucks of 10… Keep this in mind, when dirty Dougie did the reverse split it was at about 14.

1 · Reply

PsychedStocks Oct. 6 at 3:44 PM

$CYBN $CMPS $MNMD $ATAI $PFE

0 · Reply

Mastacash Oct. 6 at 3:38 PM

$CYBN sneaky bullish move last week. Continuing today. Above moving avgs not seen in months. Today in particular it looks like sometime is getting every share they can, almost like an announcement is coming.

1 · Reply

PsychedStocks Oct. 6 at 3:21 PM

$CYBN

0 · Reply

thepalace2007 Oct. 6 at 2:39 PM

$CYBN $10 coming to Cybn soon

0 · Reply

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 11, 2025, 3:59 PM EDT - 25 days ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 7:30 AM EDT - 26 days ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 7:30 AM EDT - 4 weeks ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 4, 2025, 7:30 AM EDT - 4 weeks ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 4 weeks ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 5 weeks ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 6 weeks ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 7 weeks ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 13, 2025, 5:30 PM EDT - 7 weeks ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 7, 2025, 7:30 AM EDT - 2 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 17, 2025, 7:30 AM EDT - 2 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 3 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 10:03 PM EDT - 3 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 3 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 4 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 12, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 11, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 3, 2025, 7:30 AM EDT - 4 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

May 22, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 20, 2025, 7:30 AM EDT - 5 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025, 7:30 AM EDT - 5 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 14, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 8, 2025, 7:30 AM EDT - 5 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 1, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Apr 23, 2025, 7:30 AM EDT - 5 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 21, 2025, 8:00 AM EDT - 6 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Feb 10, 2025, 9:48 PM EST - 8 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 9 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 9 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 9 months ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 10 months ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 10 months ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 11 months ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 11 months ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 13, 2024, 7:30 AM EST - 11 months ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Oct 18, 2024, 2:30 PM EDT - 1 year ago

Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +

DAVA EQNR

Oct 15, 2024, 12:30 PM EDT - 1 year ago

Cybin: Top Value Psychedelic Stock

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Sep 27, 2024, 11:48 AM EDT - 1 year ago

Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Sep 19, 2024, 5:38 PM EDT - 1 year ago

Cybin Provides Corporate Update on Upcoming Clinical Milestones

Sep 19, 2024, 8:00 AM EDT - 1 year ago

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale

LiquidThetaLEAPS Oct. 7 at 9:12 AM

0 · Reply

BobJohnBuoy666 Oct. 6 at 9:14 PM

$CYBN nice Adam / Eve double bottom. Daddy wants to get paid!

0 · Reply

PsychedStocks Oct. 6 at 6:43 PM

$CYBN $CYBHF $BBAI

0 · Reply

finck Oct. 6 at 6:34 PM

$CYBN lets get to $28 per share first and then we can start to get excited

0 · Reply

Rico_Again_Jorge Oct. 6 at 5:04 PM

$CYBN Wow. Another good time to short

0 · Reply

HughJasol Oct. 6 at 3:48 PM

$CYBN this will be back at 5 before it hits 8, let alone you pumper trucks of 10… Keep this in mind, when dirty Dougie did the reverse split it was at about 14.

1 · Reply

PsychedStocks Oct. 6 at 3:44 PM

$CYBN $CMPS $MNMD $ATAI $PFE

0 · Reply

Mastacash Oct. 6 at 3:38 PM

1 · Reply

PsychedStocks Oct. 6 at 3:21 PM

$CYBN

0 · Reply

thepalace2007 Oct. 6 at 2:39 PM

$CYBN $10 coming to Cybn soon

0 · Reply

PsychedStocks Oct. 6 at 2:38 PM

$CYBN rumors of acquisition

0 · Reply

ZRadly Oct. 6 at 1:57 PM

$CYBN STEX zip code changer😉

0 · Reply

thepalace2007 Oct. 6 at 1:25 AM

$CYBN buy it up big money is accumulating

0 · Reply

Rico_Again_Jorge Oct. 5 at 10:11 AM

$CYBN After RS, yes

0 · Reply

LiquidThetaLEAPS Oct. 4 at 7:44 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CYBN Current Share Price: $6.08 Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.51- $1.84 Scale out: $2.34-$3.01 Can Easily Capture: 60% ROI Blended DTE: 224 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Hardspot Oct. 4 at 7:03 PM

$CYBN owning this stock is is worse than when i had to watch steel magnolias with my mom and her friend.

2 · Reply

Bulltrader988 Oct. 4 at 3:47 PM

$CYBN ....👃👀 https://finviz.com/quote.ashx?t=CYBN&ty=c&ta=1&p=d

0 · Reply

PsychedStocks Oct. 4 at 3:34 PM

$CYBN $CMPS $ATAI $MNMD

1 · Reply

thepalace2007 Oct. 3 at 4:55 PM

$CYBN $10+ coming soon

3 · Reply

NVDAMillionaire Oct. 3 at 12:12 PM

$CYBN Excellent article that nails exactly where CYBN stands right now. So if you want to update your CYBN knowledge or get acquainted with CYBN, this is a must read. https://beyondspx.com/quote/CYBN/analysis/cybin-s-deuterated-edge-unlocking-psychedelic-therapeutics-for-mental-health-nyse-american-cybn

2 · Reply

Bulltrader988 Oct. 3 at 7:49 AM

$CYBN ....in play 👃👀 https://finviz.com/quote.ashx?t=CYBN&ty=c&ta=1&p=d

0 · Reply

BobJohnBuoy666 Oct. 2 at 11:36 PM

$CYBN good volume today, current 1hr chart has solid potential, possible carryover into tomorrow

0 · Reply

Market Cap	153.14M
Revenue (ttm)	0.00
Net Income (ttm)	-81.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	816,639
Avg Vol	575,072
Day's Range	N/A - N/A
Shares Out	25.19M
Stochastic %K	78%
Beta	0.63
Analysts	Strong Sell
Price Target	$80.60